Gefitinib adopts orphan kinases in leukemia

Authors
Category Primary study
JournalBlood
Year 2005
Gefitinib, an orally active small-molecule drug that is used for lung cancer therapy based on its EGFR kinase inhibitory properties, is shown to promote differentiation of leukemic cell lines and primary blasts from AML patients in an EGFR-independent fashion.
Epistemonikos ID: d6f1012678329983c44f339c91729cce3484b500
First added on: Feb 04, 2025